PMV Pharma to Present Rezatapopt Data at ENA 2026
Updated Phase 2 PYNNACLE results for the p53 reactivator rezatapopt will be shown as a late-breaking oral presentation in Barcelona.
Updated on Nov. 4, 2026 in Cancer
PMV Pharmaceuticals will present updated Phase 2 PYNNACLE results for rezatapopt, a p53 reactivator, as a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 20, 2026. The presentation will include updated data from all PYNNACLE trial cohorts.
Why it matters
The presentation will give the oncology community updated efficacy, molecular activity and safety data from the pivotal trial of rezatapopt in advanced solid tumors with a TP53 Y220C mutation. The company's ability to obtain approval of rezatapopt as a monotherapy treatment option remains a stated future expectation.
The updated data come from a registrational, single-arm Phase 2 basket trial spanning five cohorts at about 70 sites, identified as NCT04585750. The results for the TP53 Y220C population remain unreported until the presentation, and the monotherapy approval outcome is still pending.
The players
PMV Pharmaceuticals
PMV Pharmaceuticals is a precision oncology company headquartered in Princeton, New Jersey, developing rezatapopt as a p53 reactivator therapy.
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is a leading New York cancer research and treatment institution where presenter Alison M. Schram works.
The details
Alison M. Schram, M.D., of Memorial Sloan Kettering Cancer Center will present the study, titled "Efficacy, molecular activity and safety from the pivotal PYNNACLE Phase 2 trial assessing rezatapopt, a p53 reactivator, in TP53 Y220C-positive advanced solid tumors," as abstract 12LBA during Plenary Session 7. Rezatapopt holds FDA Fast Track designation for locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for TP53 Y220C-positive ovarian, fallopian tube and primary peritoneal cancers.
Timeline
November 4, 2026: PMV Pharmaceuticals announces the ENA 2026 late-breaking presentation.
November 20, 2026, 15:00 CET: Late-breaking oral presentation of PYNNACLE Phase 2 data at ENA 2026 in Barcelona.
Big Picture
The 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics is the venue for this update, placing rezatapopt's p53 Y220C clinical data within the meeting's focus on molecularly targeted cancer drugs. The presentation reports on a therapy aimed at a specific TP53 mutation rather than a tumor site.
Patients with advanced solid tumors carrying a TP53 Y220C mutation may eventually have a targeted oral treatment option if rezatapopt is approved as a monotherapy. Until then, the updated data will help clinicians assess whether the therapy fits the molecular profile of their patients.
The takeaway
Watch the November 20 presentation for the first full cohort-level efficacy and safety data on rezatapopt. Patients with TP53 Y220C-positive tumors should ask their oncologists whether clinical trial access or future approval may be relevant to their care.
What happens next
The late-breaking oral presentation of PYNNACLE Phase 2 data is scheduled for November 20, 2026, at 15:00 CET during Plenary Session 7 at ENA 2026 in Barcelona.
Further reading
For more on targeted treatments, see the Cancer section.
